Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Mar;73(6):789–793. doi: 10.1038/bjc.1996.137

Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.

J M Stouthard 1, H Goey 1, E G de Vries 1, P H de Mulder 1, A Groenewegen 1, L Pronk 1, G Stoter 1, H P Sauerwein 1, P J Bakker 1, C H Veenhof 1
PMCID: PMC2074380  PMID: 8611381

Abstract

A phase II trial investigating the anti-tumour effects of recombinant human interleukin 6 (rhIL-6) in patients with metastatic renal cell cancer was carried out. RhIL-6 (150 microgram) was administered as a daily subcutaneous injection for 42 consecutive days on an outpatient basis. Forty-nine patients were studied, 12 with and 37 without previous immunotherapy. Forty patients were evaluable for response. A partial remission was noted in two patients, stable disease in 17 and progressive disease in 21. Toxicity was moderate and reversible and consisted mainly of fever, flu-like symptoms, nausea, weight loss and hepatotoxicity. Anaemia, leucocytosis and thrombocytosis and induction of acute phase protein synthesis were noted in most patients. In 15% of the patients anti-IL-6 antibodies developed, and were neutralising in only one patient. Baseline plasma IL-6 concentrations did not correlate with tumour behaviour before or after rhIL-6 treatment. In conclusion, rhIL-6 can be safely administered on an outpatient basis for prolonged period of time and has moderate, reversible toxicity. Its administration induces IL-6-antibody production in only a minority of patients. Antitmour effects of rhIL-6 in metastatic renal cancer are limited.

Full text

PDF
789

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blay J. Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., Mercatello A., Ravault A., Tourani J. M., Moskovtchenko J. F. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992 Jun 15;52(12):3317–3322. [PubMed] [Google Scholar]
  2. Chen L., Mory Y., Zilberstein A., Revel M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2. Proc Natl Acad Sci U S A. 1988 Nov;85(21):8037–8041. doi: 10.1073/pnas.85.21.8037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gauldie J., Richards C., Baumann H. IL6 and the acute phase reaction. Res Immunol. 1992 Sep;143(7):755–759. doi: 10.1016/0923-2494(92)80018-g. [DOI] [PubMed] [Google Scholar]
  4. Gogusev J., Augusti M., Chrétien Y., Droz D. Interleukin-6 and TNF alpha production in human renal cell carcinoma. Kidney Int. 1993 Sep;44(3):585–592. doi: 10.1038/ki.1993.285. [DOI] [PubMed] [Google Scholar]
  5. Gruss H. J., Brach M. A., Mertelsmann R. H., Herrmann F. Interferon-gamma interrupts autocrine growth mediated by endogenous interleukin-6 in renal-cell carcinoma. Int J Cancer. 1991 Nov 11;49(5):770–773. doi: 10.1002/ijc.2910490523. [DOI] [PubMed] [Google Scholar]
  6. Houssiau F., Van Snick J. IL6 and the T-cell response. Res Immunol. 1992 Sep;143(7):740–743. doi: 10.1016/0923-2494(92)80014-c. [DOI] [PubMed] [Google Scholar]
  7. Ishibashi T., Asano S. IL6 and thrombocytopoiesis. Res Immunol. 1992 Sep;143(7):752–754. doi: 10.1016/0923-2494(92)80017-f. [DOI] [PubMed] [Google Scholar]
  8. Kishimoto T., Hirano T. Molecular regulation of B lymphocyte response. Annu Rev Immunol. 1988;6:485–512. doi: 10.1146/annurev.iy.06.040188.002413. [DOI] [PubMed] [Google Scholar]
  9. Koo A. S., Armstrong C., Bochner B., Shimabukuro T., Tso C. L., deKernion J. B., Belldegrum A. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother. 1992;35(2):97–105. doi: 10.1007/BF01741856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Le J. M., Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest. 1989 Dec;61(6):588–602. [PubMed] [Google Scholar]
  11. Miki S., Iwano M., Miki Y., Yamamoto M., Tang B., Yokokawa K., Sonoda T., Hirano T., Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989 Jul 3;250(2):607–610. doi: 10.1016/0014-5793(89)80805-1. [DOI] [PubMed] [Google Scholar]
  12. Mulé J. J., Custer M. C., Travis W. D., Rosenberg S. A. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol. 1992 Apr 15;148(8):2622–2629. [PubMed] [Google Scholar]
  13. Mulé J. J., McIntosh J. K., Jablons D. M., Rosenberg S. A. Antitumor activity of recombinant interleukin 6 in mice. J Exp Med. 1990 Mar 1;171(3):629–636. doi: 10.1084/jem.171.3.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Porgador A., Tzehoval E., Katz A., Vadai E., Revel M., Feldman M., Eisenbach L. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 1992 Jul 1;52(13):3679–3686. [PubMed] [Google Scholar]
  15. Ravoet C., DeGrève J., Vandewoude K., Kerger J., Sculier J. P., Lacor P., Stryckmans P., Piccart M. Tumour stimulating effects of recombinant human interleukin-6. Lancet. 1994 Dec 3;344(8936):1576–1577. doi: 10.1016/s0140-6736(94)90387-5. [DOI] [PubMed] [Google Scholar]
  16. Revel M. Growth regulatory functions of IL6 and antitumour effects. Res Immunol. 1992 Sep;143(7):769–773. doi: 10.1016/0923-2494(92)80021-c. [DOI] [PubMed] [Google Scholar]
  17. Simon R. How large should a phase II trial of a new drug be? Cancer Treat Rep. 1987 Nov;71(11):1079–1085. [PubMed] [Google Scholar]
  18. Stadler W. M., Richards J. M., Vogelzang N. J. Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst. 1992 Dec 2;84(23):1835–1836. doi: 10.1093/jnci/84.23.1835. [DOI] [PubMed] [Google Scholar]
  19. Stouthard J. M., Romijn J. A., Van der Poll T., Endert E., Klein S., Bakker P. J., Veenhof C. H., Sauerwein H. P. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol. 1995 May;268(5 Pt 1):E813–E819. doi: 10.1152/ajpendo.1995.268.5.E813. [DOI] [PubMed] [Google Scholar]
  20. Stouthard J. M., van der Poll T., Endert E., Bakker P. J., Veenhof C. H., Sauerwein H. P., Romijn J. A. Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans. J Clin Endocrinol Metab. 1994 Nov;79(5):1342–1346. doi: 10.1210/jcem.79.5.7962327. [DOI] [PubMed] [Google Scholar]
  21. Takahashi N., Brouckaert P., Fiers W. Induction of tolerance allows separation of lethal and antitumor activities of tumor necrosis factor in mice. Cancer Res. 1991 May 1;51(9):2366–2372. [PubMed] [Google Scholar]
  22. Tsukamoto T., Kumamoto Y., Miyao N., Masumori N., Takahashi A., Yanase M. Interleukin-6 in renal cell carcinoma. J Urol. 1992 Dec;148(6):1778–1782. doi: 10.1016/s0022-5347(17)37026-x. [DOI] [PubMed] [Google Scholar]
  23. Weber J., Yang J. C., Topalian S. L., Parkinson D. R., Schwartzentruber D. S., Ettinghausen S. E., Gunn H., Mixon A., Kim H., Cole D. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol. 1993 Mar;11(3):499–506. doi: 10.1200/JCO.1993.11.3.499. [DOI] [PubMed] [Google Scholar]
  24. Wirth M. P. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am. 1993 May;20(2):283–295. [PubMed] [Google Scholar]
  25. Yagoda A., Petrylak D., Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am. 1993 May;20(2):303–321. [PubMed] [Google Scholar]
  26. van Gameren M. M., Willemse P. H., Mulder N. H., Limburg P. C., Groen H. J., Vellenga E., de Vries E. G. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood. 1994 Sep 1;84(5):1434–1441. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES